title: Novel 1,5-naphthyridine PI3Kδ inhibitors, an evaluation of WO2011075628.
abstract: A small series of aryl(1-arylamino)ethyl,1,5-naphthyridine derivatives that selectively inhibit PI3Kδ was prepared. The compounds are claimed to be useful in the treatment of cancer, inflammatory and autoimmune diseases. The compounds represent further variations around a structural motif explored in a number of previous applications by the applicant.
authors.affiliation: Norman Consulting, Burnham, Bucks, UK. petrosn@bigfoot.com
authors.forename: Peter
authors.initials: P
authors.lastname: Norman
mesh_terms: D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy / Q000201:enzymology; D058534:Class I Phosphatidylinositol 3-Kinases; D015195:Drug Design; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D006801:Humans; D007249:Inflammation / Q000188:drug therapy / Q000201:enzymology; D009287:Naphthyridines / Q000737:chemistry / Q000494:pharmacology*; D009369:Neoplasms / Q000188:drug therapy / Q000201:enzymology; D010330:Patents as Topic; D000081082:Phosphoinositide-3 Kinase Inhibitors
chemical_list: D004791:Enzyme Inhibitors; D009287:Naphthyridines; D000081082:Phosphoinositide-3 Kinase Inhibitors; D058534:Class I Phosphatidylinositol 3-Kinases; C486018:PIK3CD protein, human